Revenue grew 26.3% to RMB73.4 billion in 2025, with non-IFRS profit up 36.3% to RMB6.5 billion and gross margin improving to 24.8%. The company expanded AI-powered healthcare services, launched over 100 new drugs, and strengthened its omnichannel supply chain and direct sales capabilities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.